Shiyao Innovation announced that the SYH2092 injection clinical trial application from the holding subsidiary Shiyao Group Jushi Biopharmaceutical Co., Ltd. was accepted on June 5, 2026. The “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration was recently received, agreeing to carry out clinical trials of the drug domestically, and the company will conduct clinical trials in the near future.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.